Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15483338 | 0.89 | PIK3CG (0.30) | PIK3CG | |
| SCHEMBL15483340 | 0.86 | — | — | |
| SCHEMBL21784191 | 0.84 | PIK3CG (0.32) | PIK3CG | |
| SCHEMBL15483312 | 0.83 | PIK3CG (0.38) | PIK3CG | |
| SCHEMBL15691300 | 0.82 | — | — | |
| SCHEMBL22545665 | 0.82 | — | — | |
| SCHEMBL78067 | 0.80 | PIK3CG (0.43) | PIK3CGKDM4EALDH1A1LMNAHPGD | |
| SCHEMBL21784158 | 0.76 | — | — | |
| SCHEMBL20464256 | 0.74 | PIK3CG (0.33) | PIK3CGKDM4EALDH1A1LMNAHPGD | |
| SCHEMBL12251571 | 0.74 | PIK3CG (0.33) | PIK3CGKDM4EALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163485-A1 | Heterocyclic Compounds for the Treatment of Disease | OPPILAN PHARMA LTD (GB) | 2021-06-03 | — | — | US | disclosed |
| US-20200325135-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | OPPILAN PHARMA LTD (GB) | 2020-10-15 | — | — | US | disclosed |
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-09 | — | — | US | disclosed |
| US-20200071327-A1 | Prodrugs for the Treatment of Disease | OPPILAN PHARMA LTD (GB) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325135-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, FH, TPMT | PIK3CG 4011/4885KDM4E 3643/4885ALDH1A1 562/4885 |
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | PIK3CG 2991/4885KDM4E 3111/4885ALDH1A1 2289/4885 |
| US-20210163485-A1 | Heterocyclic Compounds for the Treatment of Disease | VHL, FH, TPMT | PIK3CG 3915/4885KDM4E 3499/4885ALDH1A1 545/4885 |
| US-20200071327-A1 | Prodrugs for the Treatment of Disease | DPYD, PAICS, TYMP | PIK3CG 1828/4885KDM4E 2875/4885ALDH1A1 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.